PSMA-targeted radionuclide therapy with lutetium-177 has emerged as an effective treatment option for prostate cancer, and [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMAI&T have achieved global recognition as viable radiopharmaceuticals. This evidence concerns the gene FOLH1 and Familial prostate cancer.